HHS Expands Sickle Cell Care Nationwide with Seven New Regional Hubs

WASHINGTON, D.C.—October 20, 2026—The U.S. Department of Health and Human Services (HHS), through the Health Resources and Services Administration (HRSA), today announced seven awards through its new Sickle Cell Disease Regional Care Excellence (SoRCE) Program. The awards establish Regional Coordinating Hubs to help people with sickle cell disease access high-quality care and community services closer to home.

“Americans living with sickle cell disease should not have to travel long distances or overcome unnecessary barriers to receive effective care,” said HHS Secretary Robert F. Kennedy, Jr. “Early treatment can prevent serious complications and help patients live healthier lives. The Trump Administration is expanding access to proven treatments and specialized care so more patients can get the support they need in the communities they call home.”

Approximately 100,000 people in the United States live with sickle cell disease. Early and ongoing treatment can prevent or reduce serious complications, yet many people face barriers to preventive care, specialty services, and disease-modifying therapies. The SoRCE Program aims to improve access and quality of care while tracking indicators of quality of life.

“People living with sickle cell disease deserve access to high-quality care and support close to home,” said HRSA Administrator Tom Engels. “Through the SoRCE Program, HRSA is strengthening regional networks that connect clinical expertise with trusted community partners so more individuals and families can get the care and services they need.”

Administered by HRSA’s Maternal and Child Health Bureau, the SoRCE program expands HRSA’s regional sickle cell care network from five to seven regions. Each Regional Coordinating Hub will partner with at least three clinical-community spokes. Each spoke will include a clinical center and at least one community-based organization, connecting specialty expertise with services and support in the communities where people live.

HRSA also intends to award a contract to provide nationwide technical assistance, training, capacity building, and coordination for community-based organizations, community health workers, health centers, and regional partners.

The SoRCE Program builds on HRSA’s previous sickle cell investments, which have helped more than 75% of people with sickle cell disease across America receive disease-modifying therapy. By strengthening local care networks and the workforce that supports them, the new awards advance the Trump Administration’s focus on prevention, stronger communities, and better health outcomes for American families.

See the FY 2026 SoRCE Program award recipients.